DNAe is developing the LiDia-SEQ™ Platform, a direct-from-specimen diagnostic system that performs DNA sequencing on a microchip to provide rapid, actionable information to clinicians. This system is user-friendly and can work in a variety of hospital environments at the point of need. The LiDia-SEQ™ Platform has flexible levels of throughput to match a wide range of clinical demands.
DNAe’s initial focus is on infectious disease diagnostics, where speed and microbial DNA sequence information are important for the survival of the patient. This includes a range of tests, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to detect and identify infections that lead to sepsis.
Imperial researcher Professor Chris Toumazou is the Co-Founder of DNAe
